The HumInflammation ThemaPanel, developed by Genexpath, is a specialized panel designed for the targeted and precise analysis of inflammatory mechanisms. Using the RT-MLPSeq method, this panel enables the simultaneous quantification of 41 key genes involved in the human inflammatory response. Whether you work in the fields of autoimmune diseases, infections, oncology, or therapeutic responses, HumInflammation delivers reliable and reproducible results, essential for in-depth studies and clinical applications.
The Strengths of HumInflammation
- Precise targeting: 41 inflammation biomarkers, including cytokines, chemokines, receptors, and growth factors.
- RT-MLPSeq technology: An innovative method enabling highly specific, multiplexed gene expression analysis.
- Bias-free detection: The method avoids biases associated with traditional amplification and ensures accurate quantification, even from low RNA input.
- Compatibility with various sample types: HumInflammation is compatible with fresh, frozen, or formalin-fixed paraffin-embedded (FFPE) tissue samples, providing great flexibility.
List of the 41 Markers in the HumInflammation Panel
- Chemokines and Receptors: CCL1, CCL2, CCL3, CCL4, CCL5, CCL11, CCL15, CCL24, CXCL8, CXCL9, CXCL10
- Hematopoietic and Growth Factors: CSF1, CSF2, CSF3, PDGFB, TGFB1
- Cytokines: IL1A, IL1B, IL2, IL3, IL4, IL6, IL6R, IL7, IL10, IL11, IL12A, IL12B, IL13, IL16, IL17A, IFNA, IFNB1, IFNG, TNF, LTA (TNFB)
- Signaling Markers: ICAM1, TIMP2, TNFRSF1A, TNFRSF1B, TXLNA (IL-14)
The RT-MLPSeq Process: Advanced Technology for High-Resolution Analysis
- RNA Extraction: RNA is extracted from your samples using standard procedures. Samples may come from fresh, frozen, or paraffin-embedded (FFPE) tissues.
- Reverse Transcription into Complementary DNA (cDNA): Messenger RNA (mRNA) is converted into complementary DNA (cDNA), enabling targeted and specific gene expression analysis without interference from genomic DNA.
- Hybridization of Specific Probes: Oligonucleotide probes specifically hybridize to exon–exon junctions of cDNA. This approach ensures high-precision analysis and eliminates interference from non-target genomic sequences. The integration of Unique Molecular Identifiers (UMIs) enables the quantification of unique molecules, ensuring reliable analysis.
- Ligation and Amplification: Adjacent hybridized probes are ligated using a ligase enzyme and then amplified by PCR. Barcodes are incorporated at this stage to uniquely identify each sample, enabling precise tracking throughout the analysis process.
- Next-Generation Sequencing (NGS): High-throughput sequencing allows for the simultaneous analysis of multiple samples and dozens of genes. With only 100,000 reads required, this method delivers robust results with high sensitivity while reducing overall analysis costs.
- Bioinformatics Analysis: The NGS data are processed using the RT-MIS bioinformatics platform, enabling rapid, accurate, and reliable interpretation of results. This platform is optimized to ensure a clear understanding of the data, helping you make informed decisions for your research projects.
Why Choose RT-MLPSeq?
- Semi-quantitative method: RT-MLPSeq provides accurate assessment of biomarker expression levels, even with low RNA input.
- Multiplex analysis: Test multiple genes simultaneously for a more comprehensive view of the inflammatory response.
- Increased specificity: Probes target exon–exon junctions, reducing the risk of false positives or amplification bias.
- Flexibility: Compatible with a wide range of sample types (fresh, frozen, or FFPE tissue), making it ideal for diverse applications.
- Fast and robust results: Thanks to high-throughput sequencing and barcode integration, RT-MLPSeq delivers reliable data with full coverage of target biomarkers.
Order HumInflammation Today
HumInflammation is now available for researchers, clinicians, and laboratories seeking to explore the human inflammatory signature with precision.
Order your panel, request a personalized quote, or reach out to our team of experts for more information.
Please contact: tech@clinisciences.com